A clearer reading

Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice

Study preparation, population, findings and limitations with original source links.

Content reviewed 2026-10-25 · Local preview

Back to all research · More in Neurological models

Animal2015-01

Neurological models · CBG

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · PMID 25252936

Two experimental mouse models

Studied preparation
CBG administered in controlled experimental regimens.
Population / model
R6/2 mice and mice exposed to a chemical model of Huntington-like injury.
What was observed
Behavioral and molecular effects differed between the two models.
Interpretation limit

Preclinical models cannot establish clinical benefit in people with Huntington’s disease or validate a retail formulation.

Journal issue · Source checked 2026-10-25

Sources, registration and terms

Citation and publication date recorded; peer-review/preprint status not separately classified.

PMC full-text link is recorded; current access and reuse rights are not verified here.

No registration recorded for this paper; this is not a claim that none exists.

CBG / cannabigerol · Animal study

Package comparison guides; not clinical equivalence

Suggest a source correction

Copy a note and share it with the person who sent this preview. This page does not send or store your note.

Nothing has been sent.